DR studies lead to the identification of the IP for each selected compound. (A) Serial dilutions of the hit compound degrasyn, at the indicated final concentrations, were added to a 384-well plate. After conducting the miniaturized CR assay in triplicate, image analysis was performed (top) and binary results used to build a DR curve (bottom). (B) DR curves of other hit compounds identified in the primary screen as inhibitors of the ubiquitin pathway, along with their IPs. (C) DR curves of some of the hit compounds identified in the primary screen as inhibitors of the PDE, along with their IPs. Data reported as mean ± SD.